文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

简化3小时脓毒症集束化治疗依从性带来的生存获益与费用节约:系列前瞻性多中心观察性队列研究

Survival Benefit and Cost Savings From Compliance With a Simplified 3-Hour Sepsis Bundle in a Series of Prospective, Multisite, Observational Cohorts.
PubMed 文献 · Crit Care Med · 2017-01-01
一句话结论在三个独立的前瞻性多中心队列中,完全依从简化3小时脓毒症集束化治疗与住院死亡率降低及直接费用节约相关。

该研究为前瞻性、多中心、观察性研究,纳入三个连续独立队列(来自单一美国卫生系统)的全部严重脓毒症和脓毒性休克患者,比较完全依从3小时集束化治疗与至少一项元素不依从者的结局。集束化元素包括:抗生素前留取血培养、 parenteral抗生素在≥2项SIRS且乳酸医嘱后≤180分钟或从「时间零点」起≤60分钟内给药(以较早者为准)、乳酸结果在医嘱后≤90分钟可获得、以及从「时间零点」起≤30分钟内启动30 mL/kg IV晶体液bolus。三个队列的完全依从率分别为18.0%(1050/5819)、43.5%(739/1697)和29.2%(2115/7239);依从组住院死亡率均低于非依从组,调整后OR分别为0.72(95%CI 0.61-0.86,P<0.001)、0.60(95%CI 0.44-0.80,P=0.001)和0.84(95%CI 0.73-0.96,P=0.013)。队列2和3中依从组平均直接费用更低,调整后β分别为-$2,851(95%CI -$4,880至-822,P=0.006)和-$1,423(95%CI -$2,574至-272,P=0.015)。

要点

  • 在三个独立队列中,完全依从3小时脓毒症集束化治疗与住院死亡率降低独立相关,调整后OR分别为0.72、0.60和0.84。
  • 队列1(5819例)完全依从率18.0%,依从组死亡率22.6% vs 非依从组26.5%,调整后OR 0.72(95%CI 0.61-0.86)。
  • 队列2(1697例)完全依从率43.5%,依从组死亡率13.4% vs 非依从组17.8%,调整后OR 0.60(95%CI 0.44-0.80)。
  • 队列3(7239例)完全依从率29.2%,依从组死亡率18.1% vs 非依从组21.0%,调整后OR 0.84(95%CI 0.73-0.96)。
  • 队列2和3中依从组平均直接费用更低:队列2 $14,845 vs $20,056(调整后β -$2,851),队列3 $17,885 vs $22,108(调整后β -$1,423)。

适用人群与场景

  • 连续纳入的严重脓毒症和脓毒性休克患者,定义:感染、≥2项全身炎症反应综合征(SIRS)以及低灌注性器官功能障碍。
  • 三个队列分别来自:队列1为五家三级医院和六家社区医院;队列2为单一三级学术医疗中心;队列3为五家三级医院和四家社区医院。
  • 患者由质量改进项目识别,来自单一美国卫生系统,随访至出院。

诊断标准与关键阈值

  • 严重脓毒症和脓毒性休克定义:感染、≥2项全身炎症反应综合征(SIRS)以及低灌注性器官功能障碍。

处置流程与药物剂量

  • 集束化元素1:抗生素前留取血培养。
  • 集束化元素2:肠外抗生素在≥2项SIRS且乳酸医嘱后≤180分钟或从「时间零点」起≤60分钟内给药,以较早者为准。
  • 集束化元素3:乳酸结果在医嘱后≤90分钟可获得。
  • 集束化元素4:从「时间零点」起≤30分钟内启动30 mL/kg IV晶体液bolus。

研究设计与关键结果

  • 研究类型:前瞻性、多中心、观察性研究,三个连续独立队列。
  • 队列1:5819例,完全依从1050例(18.0%);依从组住院死亡率22.6%(604例)vs 非依从组26.5%(834例),95%CI 0.9-7.1%,调整后OR 0.72(95%CI 0.61-0.86),P<0.001。
  • 队列2:1697例,完全依从739例(43.5%);依从组住院死亡率13.4%(99例)vs 非依从组17.8%(171例),95%CI 1.0-7.9%,调整后OR 0.60(95%CI 0.44-0.80),P=0.001。
  • 队列2:平均直接费用依从组$14,845 vs 非依从组$20,056,95%CI -$4,798至-5,624,调整后β -$2,851(95%CI -$4,880至-822),P=0.006。
  • 队列3:7239例,完全依从2115例(29.2%);依从组住院死亡率18.1%(383例)vs 非依从组21.0%(1078例),95%CI 0.9-4.9%,调整后OR 0.84(95%CI 0.73-0.96),P=0.013。
  • 队列3:平均直接费用依从组$17,885 vs 非依从组$22,108,95%CI -$2,783至-5,663,调整后β -$1,423(95%CI -$2,574至-272),P=0.015。

证据类型、等级与局限

  • 证据类型:前瞻性、多中心、观察性队列研究。

对床旁实践的改变

  • 作者认为,3小时集束化治疗依从性与改善生存和节约费用相关;在三个独立队列中,完全依从组住院死亡率更低且直接费用更少。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: To determine mortality and costs associated with adherence to an aggressive, 3-hour sepsis bundle versus noncompliance with greater than or equal to one bundle element for severe sepsis and septic shock patients.

DESIGN: Prospective, multisite, observational study following three sequential, independent cohorts, from a single U.S. health system, through their hospitalization.

SETTING: Cohort 1: five tertiary and six community hospitals. Cohort 2: single tertiary, academic medical center. Cohort 3: five tertiary and four community hospitals.

PATIENTS: Consecutive sample of all severe sepsis and septic shock patients (defined: infection, ≥ 2 systemic inflammatory response syndrome, and hypoperfusive organ dysfunction) identified by a quality initiative. The exposure was full 3-hour bundle compliance. Bundle elements are as follows: 1) blood cultures before antibiotics; 2) parenteral antibiotics administered less than or equal to 180 minutes from greater than or equal to two systemic inflammatory response syndrome "and" lactate ordered, or less than or equal to 60 minutes from "time-zero," whichever occurs earlier; 3) lactate result available less than or equal to 90 minutes postorder; and 4) 30 mL/kg IV crystalloid bolus initiated less than or equal to 30 minutes from "time-zero." Main outcomes were in-hospital mortality (all cohorts) and total direct costs (cohorts 2 and 3).

MEASUREMENTS AND MAIN RESULTS: Cohort 1: 5,819 total patients; 1,050 (18.0%) bundle compliant. Mortality: 604 (22.6%) versus 834 (26.5%); CI, 0.9-7.1%; adjusted odds ratio, 0.72; CI, 0.61-0.86; p value is less than 0.001. Cohort 2: 1,697 total patients; 739 (43.5%) bundle compliant. Mortality: 99 (13.4%) versus 171 (17.8%), CI, 1.0-7.9%; adjusted odds ratio, 0.60; CI, 0.44-0.80; p value is equal to 0.001. Mean costs: $14,845 versus $20,056; CI, -$4,798 to -5,624; adjusted β, -$2,851; CI, -$4,880 to -822; p value is equal to 0.006. Cohort 3: 7,239 total patients; 2,115 (29.2%) bundle compliant. Mortality: 383 (18.1%) versus 1,078 (21.0%); CI, 0.9-4.9%; adjusted odds ratio, 0.84; CI, 0.73-0.96; p value is equal to 0.013. Mean costs: $17,885 versus $22,108; CI, -$2,783 to -5,663; adjusted β, -$1,423; CI, -$2,574 to -272; p value is equal to 0.015.

CONCLUSIONS: In three independent cohorts, 3-hour bundle compliance was associated with improved survival and cost savings.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Leisman DE, Doerfler ME, Ward MF, et al. Survival Benefit and Cost Savings From Compliance With a Simplified 3-Hour Sepsis Bundle in a Series of Prospective, Multisite, Observational Cohorts. Crit Care Med. 2017. PMID: 27941371. doi:10.1097/CCM.0000000000002184

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。